Genomic Health Accelerates Timeline for Prostate Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health said today that it has accelerated development of its prostate cancer test with the goal of launching it in 2013, a year earlier than it had previously estimated.

The firm also said that Israeli insurance firm Clalit has agreed to provide reimbursement for its Oncotype Dx colon cancer test and that it expects to report results from a second recurrence study in stage II colon cancer in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.